Company description

Corcept Therapeutics Incorporated (CORT) is a biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of severe metabolic, psychiatric, and oncologic disorders. Founded in 1998, CORT has established itself as a leader in the field of cortisol modulation, with a portfolio of patented and clinically proven drugs targeting cortisol receptors. The company's flagship product, Korlym®, is the only FDA-approved medication for the treatment of Cushing's syndrome - a rare and life-threatening disorder resulting from excess cortisol. CORT is committed to continuing its research and development efforts to expand its product pipeline and bring life-changing treatments to patients in need. With a strong financial position and a dedicated team of skilled professionals, CORT is poised for continued success in the biopharmaceutical industry.